August 2014 | OncologyLive

When Science Outpaces Payers: Molecular Diagnostics Pose Reimbursement Dilemmas

September 17, 2014

As precision medicine continues to evolve in cancer care, the development of highly sophisticated tests that leverage the explosion of knowledge about the molecular and protein characteristics of an individual patient's tumor has emerged as its own scientific frontier.

UCSF Researcher Puts Focus on AR Resistance Mechanisms

September 10, 2014

Terence Friedlander, MD, specializes in understanding the basic biology of genitourinary cancer, in particular cancer of the bladder and prostate, in developing new treatments and studying new ways to overcome treatment resistance.

Alpha-Particle Radiopharmaceuticals Moving Forward as AML Therapy

September 08, 2014

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.

Targeting the Androgen Receptor: New Hope for Aggressive Forms of Prostate and Breast Cancer

September 05, 2014

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

Novel Breast Cancer Agents Aimed at Overcoming Endocrine Therapy Resistance

August 28, 2014

Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.

Not Yet Ready for Prime Time: Lessons Learned From a Failed Molecular Marker-Based Lung Cancer Trial

August 27, 2014

Scarcely a week goes by without a report in the peer-reviewed medical literature suggesting that a novel somatic genomic alteration or a specific normal polymorphism is potentially relevant to achieving a desirable clinical outcome within cancer medicine.

O'Shaughnessy Provides Fresh Insights Into Specificity in TNBC Therapy

August 25, 2014

Although no cytotoxic agents are currently correlated with specific subtypes of triple negative breast cancer (TNBC), recent findings indicate that targeting genomic stability, antimetastatic mechanisms, and protein expression characteristics are promising approaches for future TNBC treatments.

Through the Prism of Change

August 21, 2014

In our coverage of the 13th Annual International Congress on the Future of Breast Cancer, which Physicians' Education Resource hosted in California, we focus on aspects of clinical care that may be influenced by the ever-growing body of knowledge about the molecular nature of breast cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21, 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

Evidence Builds for Electric Field Therapy in Recurrent GBM

August 19, 2014

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression